|
Systematic Review of Shengmai Injection for Cardiotoxicity Induced by Anthracyclines
YANG Min, LU Jing, MOU Jin-jin, XU Ting
2012, 9(11):
666-669.
ObjectiveTo explore the efficiency of Shengmai injection for cardiotoxicity in tumor patients induced by Anthracyclines. MethodsWe systematically retrieved the randomized controlled trials(RCTs) which were designed for Shengmai injection for cardiotoxicity in tumor patients induced by Anthracyclines.The three researchers selected the references according to the inclusion criterion, then appraised them critically and conducted meta-analysis. ResultsSix RCTs were included at last with 615 patitents, 307 in the experimental group and 308 in the control group.The two groups have statistically significant differences in every outcome we have designed: rate of abnormal electrocardiogram[RR=0.38, 95%CI(0.27,0.54), P<0.00001], change of EF[MD=-2.50, 95%CI(-3.83,-1.18), P=0.0002], change of LVDd[MD=-0.79,95%CI(-0.93,-0.66),P<0.00001], change of LVDs[MD=-0.58,95%CI(-0.82,-0.35),P<0.00001], change of FS[MD=-3.02,95%CI(-5.02,-1.01),P =0.003]. ConclusionOn current evidence, Shengmai injection is probably effective for the prevention and treatment of cardiotoxicity in tumor patients induced by Anthracyclines. However, more high quality clinical trials are needed to confirm this.
References |
Related Articles |
Metrics
|